AMGEN Inc.
NASDAQ:AMGN 2:58:16 PM EDT
Products, Regulatory
Amgen Says Source Phase 3 Trial For Tezepelumab Did Not Meet Primary Endpoint
Published: 12/22/2020 07:14 GMT
AMGEN Inc. (AMGN) - Update on Source Phase 3 Trial for Tezepelumab in Patients With Severe, Oral Corticosteroid-dependent Asthma.
Safety Profile of Tezepelumab in Trial Was Consistent With Previous Trials.
Detailed Results From Source Trial Will Be Presented at a Future Medical Meeting.
Source Trial Did Not Meet Primary Endpoint.
Amgen - Tezepelumab's Effect on Other Efficacy Parameters Was Similar to Those in Previous Studies, Including Registrational Phase 3 Navigator Study.
Safety Profile of Tezepelumab in Trial Was Consistent With Previous Trials.
Detailed Results From Source Trial Will Be Presented at a Future Medical Meeting.
Source Trial Did Not Meet Primary Endpoint.
Amgen - Tezepelumab's Effect on Other Efficacy Parameters Was Similar to Those in Previous Studies, Including Registrational Phase 3 Navigator Study.